Skip to main content
Akeso, Inc. logo

Akeso, Inc. — Investor Relations & Filings

Ticker · 9926 ISIN · KYG0146B1032 LEI · 254900ECWYGR3QW5GF30 HKEX Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9926

About Akeso, Inc.

http://www.akesobio.com

Akeso, Inc. is a commercial-stage biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative antibody drugs globally. The company integrates comprehensive drug discovery capabilities, including target validation and antibody drug development. Akeso maintains a broad and innovative therapeutic portfolio, primarily concentrated in the fields of oncology and immunology. The company has successfully advanced multiple novel therapies, including five innovative drugs with approved indications, demonstrating its commitment to bringing breakthrough treatments to market. Akeso has notably developed a lung cancer drug that has garnered significant attention within the global biotech sector.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 April 2026
Regulatory Filings
2026-05-06 English
Notification Letter and Reply Form to Non-registered Holders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications
Regulatory Filings Classification · 1% confidence The document is a reminder letter to non-registered shareholders about the Company’s adoption of electronic dissemination of corporate communications and includes a reply form to request printed communications. It does not contain actual financial statements, voting results, dividend details, or specific report content, nor is it announcing a particular report release. It is a general regulatory announcement regarding corporate communications procedures, which does not neatly fit any of the more specific categories. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-04-29 English
Notification Letter and Reply Form to Registered Shareholders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications
Regulatory Filings Classification · 1% confidence The document is a reminder letter to registered shareholders regarding the arrangement of electronic dissemination of corporate communications and includes a reply form for shareholders to opt into electronic or printed formats. It is not presenting any financial results, meeting materials, proxy solicitation for votes, or corporate actions like dividends or M&A. It serves as a general regulatory compliance notice and falls under the fallback category of Regulatory Filings (RNS).
2026-04-29 English
2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Regulatory Filings
2026-04-29 English
2025 ANNUAL REPORT
Regulatory Filings
2026-04-29 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Earnings Release Classification · 1% confidence The document is titled “Annual Results Announcement for the Year Ended December 31, 2025” filed to the Hong Kong Stock Exchange. It contains consolidated IFRS financial highlights, a detailed Management Discussion and Analysis, and is an initial public release of the year-end results. It is not the full statutory annual report (i.e., it does not include all corporate governance disclosures or the complete set of statutory financial statements), but rather the official earnings announcement of the year’s performance. Therefore, it best fits the definition of an Earnings Release (ER). FY 2025
2026-03-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.